CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 300 enrolled
Drug / intervention
Alpha-Lipoic Acid(α-LA) +1 moredrug
Likely dose
Alpha-Lipoic Acid(α-LA) 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03491969
NCT03491969Phase 4Completed
CompareCT.gov

Clinical Study of Lipoic Acid on Ischemic Heart Failure

Shanghai Zhongshan Hospital·interventional·Posted Apr 9, 2018·Updated Jul 14, 2025

In Brief

A Phase 4 clinical trial evaluating Alpha-Lipoic Acid(α-LA) and Placebos for Ischemic Heart Failure. Completed, enrolled 300 participants across 1 site.

Detailed Summary

The study will evaluate the efficacy of alpha-lipoic acid(α-LA) on mortality in patients with ischemic heart failure (NYHA Class II - IV and EF =\< 50%).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Heart Failure
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 9, 2018
Enrollment StartJan 1, 2019
Primary CompletionFeb 1, 2025
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 8.2 years ago

Interventions

Alpha-Lipoic Acid(α-LA)drug

200 mg, po, tid

Placebosdrug

200 mg, po, tid